Home » Stocks » Evogene

Evogene Ltd. (EVGN)

Stock Price: $1.50 USD 0.17 (12.78%)
Updated Aug 14, 2020 11:54 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 38.63M
Revenue (ttm) 586,000
Net Income (ttm) -18.11M
Shares Out 25.75M
EPS (ttm) -0.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $1.50
Previous Close $1.33
Change ($) 0.17
Change (%) 12.78%
Day's Open 1.43
Day's Range 1.39 - 1.52
Day's Volume 641,637
52-Week Range 0.75 - 1.83

More Stats

Market Cap 38.63M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 25.75M
Float 22.49M
EPS (basic) -0.7
EPS (diluted) -0.81
FCF / Share -0.72
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 35,340
Short Ratio 0.46
Short % of Float 0.25%
Beta 0.35
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 65.92
PB Ratio 0.78
Revenue 586,000
Operating Income -21.17M
Net Income -18.11M
Free Cash Flow -18.57M
Net Cash 43.91M
Net Cash / Share 1.70
Gross Margin 71.50%
Operating Margin -3,611.95%
Profit Margin -2,405.30%
FCF Margin -3,168.26%
ROA -26.05%
ROE -49.56%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$8.00*
Low
8.00
Current: $1.50
High
8.00
Target: 8.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.751.753.386.5411.1314.5117.5817.0714.9012.56
Revenue Growth-56.9%-48.33%-48.3%-41.23%-23.31%-17.46%2.98%14.57%18.61%-
Gross Profit0.420.300.540.902.874.807.477.526.656.75
Operating Income-21.17-19.99-21.95-21.09-17.92-15.26-8.72-3.13-3.18-1.98
Net Income-18.11-20.76-20.84-19.59-17.21-14.53-8.88-2.520.65-6.97
Shares Outstanding25.7525.7525.6725.4425.3524.9024.0724.07--
Earnings Per Share-0.70-0.81-0.81-0.77-0.68-0.58-0.45-0.140.03-0.48
Operating Cash Flow-17.67-15.16-15.93-11.69-12.41-8.90-5.27-1.892.13-2.84
Capital Expenditures-0.90-0.37-0.59-0.80-2.01-3.56-1.61-2.93-3.75-1.40
Free Cash Flow-18.57-15.54-16.52-12.50-14.41-12.46-6.88-4.82-1.62-4.24
Cash & Equivalents46.8854.4771.7688.1610111612755.1358.790.00
Total Debt2.97---------
Net Cash / Debt43.9154.4771.7688.1610111612755.1358.790.00
Assets71.3658.6977.6095.9911312813764.8667.89-
Liabilities11.158.398.228.708.8411.5012.5616.6019.80-
Book Value50.1450.0569.3887.2910411612548.2648.09-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Evogene Ltd.
Country Israel
Employees 143
CEO Ofer Haviv

Stock Information

Ticker Symbol EVGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: EVGN

Description

Evogene Ltd., a biotechnology company, engages in developing various products for life science markets through the use of computational predictive biology platform in the United States, Israel, Germany, Brazil, and internationally. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Application segment develops enhanced castor bean seeds to serve as a feedstock source for industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and multi drug resistant organisms. The company also provides medical cannabis products. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF, Corteva, Bayer, and ChemChina. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.